TRT microdosing explained

Splitting one weekly testosterone dose into smaller, more frequent shots is a scheduling change, not a new drug — here's what the pharmacokinetics actually say about daily, EOD, and E3.5D protocols.

"TRT microdosing" describes splitting a testosterone dose into smaller amounts given more often — daily, every other day (EOD), or every 3.5 days — instead of the more familiar once- or twice-weekly injection. The compound and the total weekly amount usually don't change; only the size and spacing of each individual shot do. It isn't a different drug or a way around monitoring — it's a scheduling choice some clinicians and patients use to chase the same underlying goal: a flatter blood-level curve, with less of a symptom "roller-coaster" between injections.

Why smaller, more frequent doses can mean steadier levels

The logic follows directly from pharmacokinetics. Every injected dose of testosterone rises to a peak and then decays toward a trough before the next one — the size of that swing depends on the dose and on how quickly the ester clears. Shrink the dose and shorten the interval by roughly the same factor, and the peak comes down while the trough comes up, narrowing the gap between the two. Weekly subcutaneous testosterone cypionate has already been shown to stay "stable and remained well within the normal range" between injections, with only a modest dip in the day or two before the next dose.¹ Comparative pharmacokinetic modeling across formulations puts the peak-to-trough ratio for weekly subQ injections at roughly 1.8, versus 2 to 5.3 for less frequent intramuscular dosing² — and daily or EOD dosing compresses that ratio further still, at least in theory.

In practice this matters most to people who notice mood, energy, or libido dip in the day or two before their next injection — a "crash" that tracks with the trough. Flattening the curve doesn't change total weekly testosterone exposure; it changes how much that exposure varies hour to hour. You can model this trade-off for your own numbers with the half-life calculator, which turns a given ester and interval into a personal blood-level curve instead of a rule of thumb.

Daily vs EOD vs E3.5D: how the ester's half-life sets the floor

Not every testosterone ester tolerates every schedule. Injectable esters clear at very different rates: testosterone propionate has an elimination half-life of roughly 0.8 days, while testosterone enanthate sits around 4.5 days; cypionate behaves close enough to enanthate that the two are treated as functionally interchangeable in practice.³ That difference decides how much scheduling room you actually have. Propionate's short half-life makes daily or EOD injection close to mandatory — space the shots any further apart and you reintroduce the exact peak-and-trough swing microdosing is meant to avoid. Cypionate and enanthate, with half-lives closer to a week, tolerate a much wider range of schedules — weekly, twice-weekly, EOD, or daily can all keep levels within a normal range, which turns the choice into one about comfort and stability preference rather than pharmacokinetic necessity.

Steady state — the point where the amount you inject each interval equals the amount clearing out, so levels stop climbing — takes three to five dosing intervals to reach regardless of which schedule you pick. A phase II study of weekly subcutaneous testosterone enanthate found levels approached steady state by the third injection, with dose-proportional exposure between the 50 mg and 100 mg arms.⁴ That timeline is why most clinicians wait roughly a month to six weeks after any schedule change before drawing labs — checking sooner mostly captures the transition, not the true baseline.

See how the injection route interacts with these intervals in our SubQ vs IM testosterone guide — most microdosing protocols pair frequent small doses with subcutaneous injection specifically, because the smaller insulin needle is what makes daily dosing realistic to actually stick with.

How to convert a weekly dose into a daily or EOD protocol

The starting math is simple: take your current total weekly dose and divide it across the new number of injections. A 100 mg/week dose becomes roughly 14 mg/day (100 / 7) on a daily protocol, or about 33 mg per shot on an EOD protocol (100 / 3.5 injections a week). Because total weekly exposure stays the same, this isn't a dose increase — it's the same testosterone delivered on a flatter schedule. What does change is the equipment: daily and EOD micro-doses are usually small enough that people switch from a standard 3 mL syringe to an insulin syringe, which also means getting comfortable reading finer gradations (units or tenths of a mL) accurately. Running the conversion through the TRT dose calculator avoids doing that arithmetic by hand and flags rounding errors before they turn into a measurable under- or over-dose.

1. Confirm your current weekly total dose and ester with your prescriber before changing anything.
2. Pick a target interval — daily, EOD, or E3.5D — based on the ester's half-life and your own tolerance for injection frequency.
3. Divide the weekly total by the number of injections per week to get the per-injection dose.
4. Switch to an insulin syringe sized for the smaller volume, and confirm the concentration (mg/mL) on your vial matches your calculation.
5. Hold the new schedule for at least four to six weeks before drawing labs — that's roughly how long cypionate or enanthate needs to approach steady state.

Potential benefits: steadier mood and energy — and maybe lower E2/hematocrit

The clearest, best-supported benefit of frequent small dosing is the flatter curve described above — smaller peaks, higher troughs, and, for people whose symptoms track the swing, a steadier day-to-day feel. Two secondary benefits get mentioned often but rest on thinner evidence. The first is estradiol: because testosterone aromatizes to estradiol partly in proportion to how high and how fast levels spike, a flatter testosterone curve plausibly produces a flatter estradiol curve too. A cohort of transgender patients on stable weekly subcutaneous testosterone saw estradiol suppressed into target range in the large majority of cases, with hematocrit staying within the normal adult range in every patient followed.⁵ The second is hematocrit more broadly: a matched-cohort study comparing delivery modalities found intramuscular injections raised hematocrit more over 16 weeks than subcutaneous pellets, while gel actually lowered it slightly⁶ — consistent with the idea that large, infrequent peaks drive more erythropoietin stimulation than smaller, steadier exposure.

Trade-offs: more injections, more room for error

Frequent dosing doesn't only add benefits — it adds logistics. Daily or EOD protocols mean more needle sticks, more supplies to carry while traveling, and more decision points where a missed or doubled dose can happen. Site rotation becomes more important, not less, because the same small patch of abdomen gets used far more often than on a weekly schedule. There's also a real evidence gap worth naming honestly: most of the frequency-comparison data available comes from studies of weekly versus less-frequent schedules — one trial found weekly testosterone produced meaningfully better muscle-fiber outcomes than monthly dosing in older men, underscoring that frequency itself affects results.⁷ But no large randomized trial has compared daily or EOD micro-dosing against weekly dosing for hard outcomes like cardiovascular risk or bone density. That doesn't make frequent micro-dosing unsafe — the underlying esters have decades of safety data at other intervals⁸ — it means the specific frequency is running somewhat ahead of frequency-specific outcome evidence.

What to monitor, and how to talk to your prescriber about switching

Changing your injection frequency doesn't change what needs monitoring — it changes when you should check it. Standard TRT follow-up calls for labs roughly six to eight weeks after starting or meaningfully changing therapy, with hematocrit checked in the first year and periodically after.⁸ After switching schedules, that same window applies: give the new protocol time to reach steady state, then recheck total and free testosterone, estradiol, and hematocrit rather than judging the switch by how you feel in the first week or two. Bring the actual numbers, not just a request, to that conversation — see our TRT bloodwork guide for what to test and when. Frame it as a schedule change your prescriber signs off on and monitors, not a self-directed protocol swap; some clinicians are comfortable with daily or EOD micro-dosing and some prefer weekly, and both positions can be reasonable given how thin the frequency-specific trial data still is.

If you're weighing this switch, it helps to actually see the curve before you commit to it rather than estimate by feel. Peptide Me lets you build a schedule — daily, EOD, E3.5D, or weekly — set reminders that match it, and forecast your projected blood-level curve for a given ester and dose before you change anything, then log real doses against that forecast afterward. Explore more testosterone-dosing tools and guides in the TRT hub.

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. McFarland J, Craig W, Clarke NJ, Spratt DI. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. J Endocr Soc. 2017;1(8):1095-1103. https://pmc.ncbi.nlm.nih.gov/articles/PMC5686655/
2. Pastuszak AW, Gittelman M, Tursi JP, et al. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022;10(2):209-222. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293229/
3. Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012. https://www.cambridge.org/core/books/testosterone/B0C41B578931047CB6DBB7228CA9F7F6
4. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. https://pmc.ncbi.nlm.nih.gov/articles/PMC4721027/
5. Spratt DI, Stewart II, Savage C, et al. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection. J Clin Endocrinol Metab. 2017;102(7):2349-2355. https://academic.oup.com/jcem/article/102/7/2349/3098651
6. Reddy R, Diaz P, Blachman-Braun R, et al. Prevalence of secondary erythrocytosis in men receiving testosterone therapy: A matched-cohort analysis of intranasal gel, injections, and pellets. Can Urol Assoc J. 2023;17(7):E202-E207. https://pubmed.ncbi.nlm.nih.gov/37068153/
7. Fitts RH, Peters JR, Dillon EL, et al. Weekly Versus Monthly Testosterone Administration on Fast and Slow Skeletal Muscle Fibers in Older Adult Males. J Clin Endocrinol Metab. 2015;100(2):E223-E231. https://pmc.ncbi.nlm.nih.gov/articles/PMC4318887/
8. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465